Grants in other countries

Oncopeptides is committed to support external organisations to improve health and the healthcare community, access to care, to help advance scientific breakthroughs and improve the lives of patients with difficult-to-treat hematological diseases.

Due to the recent news that Oncopeptides has voluntarily withdrawn PEPAXTO® in the U.S. and will close the U.S. commercial business unit, we will not consider any grants for 2022, unfortunately. We sincerely thank you for your support and interest in Oncopeptides and the treatment of patients with relapsed or refractory multiple myeloma.

Independent Educational Grants

Oncopeptides supports external initiatives in our areas of focus through Educational Grants that are independent or accredited. The scope is medical and/or scientific educational activities and initiatives aimed at healthcare professionals, scientists and patients. Throughout the year we are accepting requests with focus on the unmet need in Relapsed and Refractory Multiple Myeloma (RRMM).

Read more